

Non-Insulin Therapies for Diabetes Market at a compound annual growth rate (CAGR) of 6.9%

The Business Research Company's Non-Insulin Therapies For Diabetes Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033



LONDON, GREATER LONDON, UK, August 20, 2024 /EINPresswire.com/ --

The global [non-insulin therapies for diabetes market](#) has shown robust

growth in recent years. It is projected

to increase from \$18.71 billion in 2023 to \$19.98 billion in 2024, reflecting a compound annual growth rate (CAGR) of 6.8%. Despite challenges in the healthcare landscape, the market is expected to expand significantly, reaching \$26.14 billion by 2028 at a compound annual growth rate (CAGR) of 6.9%, driven by the rising prevalence of diabetes and advancements in treatment technologies.

“

You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs
”

*The Business Research
Company*

Rising Diabetes Prevalence Drives Market Expansion

The increasing prevalence of diabetes is a key driver for the non-insulin therapies market. Factors contributing to this rise include sedentary lifestyles, unhealthy diets, and aging populations. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, and this number is projected to

reach 643 million by 2030 and 783 million by 2045. This growing patient population necessitates effective management solutions, boosting the demand for non-insulin therapies that enhance insulin sensitivity, reduce glucose production, and improve glycemic control.

Explore comprehensive insights into the global non-insulin therapies for diabetes market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=16494&type=smp

Key Players and Market Trends

Major players in the non-insulin therapies market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, and others. These companies are focusing on developing personalized diabetes management systems to improve patient outcomes. For example, Eli Lilly and Company launched the Tempo personalized diabetes management platform in November 2022, which includes innovative components such as the Tempo Smart Button and the TempoSmart app.

Trends Shaping the Market

Key trends in the market include advancements in oral and injectable medications, innovations in drug delivery systems, and the expansion of telemedicine. The growing preference for oral medications and combination therapies, alongside technological progress in digital health solutions, is expected to drive market growth. Notable developments include enhanced oral peptide delivery systems and advanced combination therapies that cater to diverse patient needs.

Segments:

- Drug Class: Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Analogs, Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors
- Route of Administration: Oral, Intramuscular
- Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
- Application: Monitoring, Diagnosis, Treatment, Other Applications

Geographical Insights: North America Leading the Market

North America was the largest region in the non-insulin therapies for diabetes market in 2023 and is expected to continue leading in the forecast period. The comprehensive report provides detailed insights into regional dynamics, market trends, and growth opportunities across various geographies.

Explore the report store to make a direct purchase of the report

<https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report>

Non-Insulin Therapies For Diabetes Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Non-Insulin Therapies For Diabetes Global Market Report 2024 by The Business Research

Company is the most comprehensive report that provides insights on [non-insulin therapies for diabetes market size](#), non-insulin therapies for diabetes market drivers and trends, non-insulin therapies for diabetes market major players, competitors' revenues, market positioning, and market growth across geographies. The non-insulin therapies for diabetes market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Non-injectable Insulin Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report>

Peptide Therapeutics Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report>

Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+ +44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

X

LinkedIn

YouTube

This press release can be viewed online at: <https://www.einpresswire.com/article/736044579>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.